Our CEO Alessandro Mantell leading from the front! A great testimonial from one of our longest-standing partners in the CDMO space. "Top notch service provided by Alessandro and Mantell Associates. I have worked with them to rapidly build multiple commercial organizations." #testimonialtuesday #clienttestimonial #recommendation
Mantell Associates
Vermittlung von Führungskräften
City of London, England 84.994 Follower:innen
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
Info
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
Externer Link zu Mantell Associates
- Branche
- Vermittlung von Führungskräften
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- City of London, England
- Art
- Privatunternehmen
- Gegründet
- 2019
- Spezialgebiete
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals und Highly Potent Active Pharmaceutical Ingredients
Orte
-
Primär
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Beschäftigte von Mantell Associates
Updates
-
Bridge Biotherapeutics, Inc., a clinical-stage biotechnology company, has formed a strategic alliance with HitGen Inc., a leading Chinese drug discovery platform company, to accelerate the development of novel anticancer drug candidates. The collaboration builds upon the success of initial hit finding and identification work utilising HitGen Inc.'s DNA-encoded library (DEL) technology. Read more: https://lnkd.in/esAZgCVF #drugdiscovery #anticancer #cancertherapeutics
-
eXmoor Pharma, a provider of cell and gene therapy manufacturing services, has achieved a significant milestone with the receipt of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This authorization allows eXmoor to manufacture good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials. Read more: https://lnkd.in/ec-aqu8x #celltherapy #RNAResearch #FDAApproval #PharmaCompliance
eXmoor Pharma Receives MIA(IMP) License for Cell & Gene Therapy
contractpharma.com
-
Novartis has announced the formation of Borealis Biosciences, Inc., an independent, discovery-stage biotechnology company focused on developing next-generation xRNA-based medicines for kidney diseases. The new company is a result of a partnership between Novartis and Versant Ventures, and is based in Vancouver, Canada. Read more: https://lnkd.in/eF7ADYyw #kidneydisease #advancedtherapies #xRNA
Novartis and Versant Partner to Form Kidney Disease Biotech
contractpharma.com
-
New opportunity! COO - Diagnostics - France. Mantell Associates has formed a partnership with an innovative Diagnostics organisation who is seeking a Chief Operating Officer to lead company operations. Apply for this role online - https://lnkd.in/gbMdhyPJ - or contact George Hebden Lee on +44 (0)20 3854 7700. #coojobs #leadership #clevel
Chief Operating Officer – Diagnostics
https://www.mantellassociates.com
-
Tom Bryan discusses the impending Windsor Framework’s impact on the Pharmaceutical industry and outlines key preparations that businesses should consider to ensure compliance and competitiveness. Read more below: https://lnkd.in/eDQi4g5r #windsorframeworks #pharmanews #compliance
The Impending Windsor Framework’s Impact on the Pharmaceutical Industry
https://www.mantellassociates.com
-
Great feedback for Sharleney Chandraratna from a candidate who recently started their new role! "Working with Sharleney Chandraratna was such a pleasure! She is really dedicated to her work and so nice as well. She anticipated every question that I had before I even asked her and also provided me with good advice. She was also there to listen to me and represent me in the best way possible. Thank you so much again Sharleney!" Contact Sharleney on +44 (0)20 3854 7700. #testimonialthursday #recruitmentlondon #testimonial
-
-
As Eli Lilly and Company continues to capitalize on its trove of Mounjaro and Zepbound cash with major outside deals, the company’s early external innovation and collaboration arm, Lilly Catalyze360, is welcoming all comers into the fold. Read more below: https://lnkd.in/eyRqHAB8 #therapeutics #biotechnews #healthcarenews
'We're pretty prolific': Lilly Catalyze360 looks to connect with emerging biotechs across 'all areas'
fiercebiotech.com
-
The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech SE-partnered antibody-drug conjugate (ADC) after the companies confirmed that only lower doses will be used. Read more below: https://lnkd.in/ernpTGRW #antibodies #adc #fda
FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses
fiercebiotech.com
-
CiVentiChem, a CDMO, has completed a new facility, significantly expanding its manufacturing capacity by 300%. This state-of-the-art facility will focus on producing Regulatory Starting Materials (RSMs) and intermediates to support small molecule clinical and commercial needs. Read more below: https://lnkd.in/g57BEnZ7 #cdmo #pharmamanufacturing #smallmolecule
CiVentiChem’s New Facility Increases Capacity by 300%
contractpharma.com